Andrew P. Han

Abandoning the idea of cohorts and the associated idea of a six-month residence period are the biggest changes Illumina Ventures is making to the program.

PacBio said it will provide reagent donations and discounts to Radboud University Medical Center, as well as technical and bioinformatics expertise.

Francis deSouza's sudden departure over his signature Grail deal leaves analysts and customers wondering what's next for Illumina.

As part of a lawsuit against 10x Genomics, Vizgen has alleged that Harvard improperly gave spinout ReadCoor an exclusive license to tech developed under an NIH grant.

In its petitioner's brief, Illumina and Grail called the FTC an "unconstitutional agency" and ask the court to revers the commission's decision.

The lawsuits come at the advent of a new regime for intellectual property management, the European Union's Unitary patent system.

Shareholders voted to appoint Carl Icahn's nominee Andrew Teno, at the expense of John Thompson, but kept CEO Francis deSouza on the board.

Two advisory firms have recommended ousting board chair John Thompson, while Illumina has magnified allegations that Carl Icahn's company is "Ponzi-like."

Using Arima's technology, NYU researchers were able to identify a novel rearrangement in the PDL-1 gene in a pediatric brain tumor, which led to treatment with immunotherapy.

NanoString said it disagrees with the German court and plans to appeal the decision. Moreover, it is trying to have the patent invalidated by the German Federal Patent Court.